Zacks Investment Research lowered shares of Edap Tms (NASDAQ:EDAP) from a hold rating to a sell rating in a research note published on Thursday.
According to Zacks, “EDAP TMS S.A. develops, produces, markets and distributes minimally invasive medical devices, primarily for the treatment of urological diseases. They currently produce and market devices for treatment of benign prostate hyperplasia and urinary tract stones. They are also developing a third range of products for minimally invasive destruction of certain types of tumors. “
Other equities research analysts have also issued research reports about the company. HC Wainwright reissued a buy rating and issued a $6.50 target price on shares of Edap Tms in a research report on Wednesday, May 16th. ValuEngine raised Edap Tms from a hold rating to a buy rating in a research report on Friday, June 8th. Finally, TheStreet raised Edap Tms from a d+ rating to a c rating in a research report on Tuesday, June 26th.
Edap Tms (NASDAQ:EDAP) last released its quarterly earnings data on Wednesday, August 29th. The medical equipment provider reported ($0.03) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.02) by ($0.01). Edap Tms had a negative net margin of 3.55% and a negative return on equity of 4.04%. The business had revenue of $10.14 million for the quarter, compared to the consensus estimate of $10.74 million. research analysts expect that Edap Tms will post -0.03 earnings per share for the current year.
A hedge fund recently raised its stake in Edap Tms stock. Archon Capital Management LLC boosted its position in Edap Tms SA (NASDAQ:EDAP) by 7.5% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,019,011 shares of the medical equipment provider’s stock after buying an additional 71,336 shares during the quarter. Edap Tms makes up about 0.2% of Archon Capital Management LLC’s portfolio, making the stock its 14th biggest position. Archon Capital Management LLC owned about 3.51% of Edap Tms worth $2,364,000 at the end of the most recent reporting period. 8.13% of the stock is currently owned by institutional investors.
About Edap Tms
EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. The company operates in two divisions: High Intensity Focused Ultrasound (HIFU), and Urology Devices and Services (UDS).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Edap Tms Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms and related companies with MarketBeat.com's FREE daily email newsletter.